THERAPEUTIC AGENT OR TREATMENT METHOD FOR PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOCYTIC LEUKEMIA (ALL) HAVING IKZF1 MUTATION

摘要

A pharmaceutical composition for treating Philadelphia chromosome-positive lymphocytic leukemia and including a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative is provided as a result of the present invention. In addition, a method for treating Philadelphia chromosome-positive lymphocytic leukemia is provided that includes a step in which a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative are administered to a patient suffering from Philadelphia chromosome-positive lymphocytic leukemia.